Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Earnings Data
Report Date
Nov 06, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.54Last Year’s EPS
-0.59Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant achievements in strategic partnerships and promising clinical results for certepetide. Financial management appears strong with reduced costs and an extended cash runway. However, the company's minimal current revenue and dependency on future funding are concerning. Despite these challenges, the highlights slightly outweigh the lowlights, suggesting cautious optimism.Company Guidance
Strategic Alliances and Collaborations
Lisata signed a research agreement with Catalent and formed a strategic alliance with GATC Health, enhancing their development capabilities and exploring new drug development candidates.
Encouraging Preliminary Trial Results
Preliminary results from ASCEND and iLSTA trials showed promising data for certepetide, indicating positive signals in progression-free survival and objective response rates.
Expense Management and Financial Position
Operating expenses decreased by 10.6% from the previous year, with a reduction in research and development expenses by 13.4%, demonstrating effective cost management.
Patent Extension
A new composition of matter patent for certepetide was issued, extending protection until March 2040, strengthening the company's intellectual property position.
Cash Runway Extension
With $22 million in cash and equivalents, the company expects to support current operations into the fourth quarter of 2026.
LSTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LSTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $2.80 | $2.60 | -7.14% |
May 08, 2025 | $2.37 | $2.10 | -11.39% |
Feb 27, 2025 | $2.40 | $2.38 | -0.83% |
Nov 12, 2024 | $2.91 | $2.79 | -4.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lisata Therapeutics (LSTA) report earnings?
Lisata Therapeutics (LSTA) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).
What is Lisata Therapeutics (LSTA) earnings time?
Lisata Therapeutics (LSTA) earnings time is at Nov 06, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LSTA EPS forecast?
LSTA EPS forecast for the fiscal quarter 2025 (Q3) is -0.54.